During the past decade, Gallipoli Medical Research Foundation conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 6 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gallipoli Medical Research Foundation" #1 sponsor was "EMD Serono Research & Development Institute, Inc." with 2 trials, followed by "Gilead Sciences" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Arcus Biosciences, Inc." with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gallipoli Medical Research Foundation" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Gallipoli Medical Research Foundation" are "Melanoma" (3 trials), "Bladder Cancer" (2 trials), "Colorectal Cancer" (2 trials), "Merkel Cell Carcinoma" (2 trials) and "Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "Gallipoli Medical Research Foundation" in a lesser frequency.

Most popular intervention types in "Gallipoli Medical Research Foundation" are "Drug" (14 trials), "Biological" (4 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Nivolumab" (2 trials), "ABI-H2158" (1 trials), "Avelumab" (1 trials) and "Avelumab Weekly" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gallipoli Medical Research Foundation" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Gallipoli Medical Research Foundation". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Gallipoli Medical Research Foundation, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Gallipoli Medical Research Foundation, 4 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".